Concurrent Eosinophilia and Monocytosis: Diagnostic Approach
In a 71-year-old man with fatigue, malaise, and concurrent eosinophilia and monocytosis, you must systematically exclude secondary causes first, then investigate for primary hematologic neoplasms—particularly chronic myelomonocytic leukemia (CMML), myeloid/lymphoid neoplasms with tyrosine kinase fusions, and systemic mastocytosis.
Primary Differential Diagnosis Framework
The combination of elevated eosinophils and monocytes requires a structured evaluation based on current WHO 2022 classification 1, 2:
Secondary (Reactive) Causes to Exclude First
- Parasitic infections (especially Strongyloides stercoralis—most common parasitic cause) 1, 3
- Allergic disorders (account for ~80% of secondary eosinophilia): asthma, drug reactions, atopic conditions 1, 3
- Fungal allergy (particularly important if IgE ≥1000 IU/L—91% predictive of fungal/parasitic etiology) 3
- Solid tumors and lymphoid malignancies (Hodgkin lymphoma, T-cell lymphomas—more common in advanced disease) 1
- Inflammatory/autoimmune conditions 4
Primary (Clonal/Neoplastic) Causes
When secondary causes are excluded, consider these hematologic neoplasms:
1. Chronic Myelomonocytic Leukemia (CMML)
This is critical given the patient's age and presentation 5:
- Requires persistent monocytosis >1×10⁹/L
- Blasts <20% in blood/marrow
- Dysplasia in ≥1 cell lineage OR clonal cytogenetic/molecular abnormality
- Must exclude BCR-ABL1, PDGFRA, PDGFRB rearrangements
- CMML with eosinophilia is a recognized subtype when eosinophils >1.5×10⁹/L 5
- Monocytosis strongly associates with ASXL1 (OR 2.91), SRSF2 (OR 2.2), and TET2 (OR 2.2) mutations 6
2. Myeloid/Lymphoid Neoplasms with Tyrosine Kinase Fusions (MLN-eo-TK)
- Screen for PDGFRA, PDGFRB, FGFR1, JAK2, ABL1, FLT3 rearrangements 1, 2
- Critical to identify because PDGFRA/PDGFRB-rearranged cases respond dramatically to imatinib 2, 4
- FGFR1-rearranged cases now have targeted therapy (pemigatinib) 2
3. Systemic Mastocytosis with Associated Hematologic Neoplasm (SM-AHN)
- Highest leukocyte, monocyte, and eosinophil counts occur in SM-AHN 6
- Check serum tryptase (elevated in 14.5% of eosinophilia cases, though mastocytosis is rare) 3
- Monocytosis/eosinophilia combination in advanced SM predicts poor prognosis 6
4. Lymphocyte-Variant Hypereosinophilic Syndrome (L-HES)
- Clonal T-cells with aberrant immunophenotype (CD3⁻CD4⁺, CD3⁺CD4⁻CD8⁻) 1
- Elevated IgE and TARC levels
- 10-20% risk of progression to T-cell lymphoma 1
- Flow cytometry with T-cell immunophenotyping essential
Mandatory Diagnostic Workup
Initial Laboratory Assessment
- Complete blood count with differential (absolute eosinophil and monocyte counts)
- Serum IgE level (≥1000 IU/L suggests fungal/parasitic cause) 3
- Serum tryptase 3
- Vitamin B12 (elevated in myeloproliferative variants) 1
- Troponin (cardiac involvement assessment) 7
- Liver function tests 7
Molecular/Cytogenetic Testing (Essential for Primary Eosinophilia)
- Tyrosine kinase fusion screening: PDGFRA, PDGFRB, FGFR1, JAK2, ABL1, FLT3 1, 2
- BCR-ABL1 (to exclude CML) 5
- Standard karyotype
- Next-generation sequencing panel for myeloid mutations (ASXL1, SRSF2, TET2, JAK2, RAS) 5, 6
Bone Marrow Evaluation
- Morphology for dysplasia and blast percentage 5
- Flow cytometry for aberrant T-cell populations 1
- Cytogenetics and FISH
- Assessment for fibrosis 1
Infectious/Allergic Workup
- Stool ova and parasites (×3), Strongyloides serology 1
- Aspergillus-specific IgE (if respiratory symptoms) 3
- HIV testing 4
Prognostic Implications
In advanced myeloid neoplasms with monocytosis/eosinophilia 6:
- Monocytosis ≥1.1×10⁹/L: median OS 2.9 vs 4.8 years (p<0.001)
- Eosinophilia ≥1.5×10⁹/L: median OS 1.7 vs 5.0 years (p<0.001)
- Combined elevation creates 3-tiered risk model (median OS: 1.60 vs 3.04 vs 6.94 years)
Critical Pitfalls to Avoid
- Do not delay evaluation for tyrosine kinase fusions—these are immediately treatable with targeted therapy 2, 4
- Do not assume reactive cause in elderly patients—CMML is common in this age group and presents with subtle dysplasia 5
- TCR gene rearrangement alone is insufficient for L-HES diagnosis—can occur in other eosinophilic disorders 1
- Cardiac evaluation is mandatory—eosinophil-mediated cardiac damage can be rapidly fatal 7
- Elevated tryptase does not equal mastocytosis—occurs across multiple eosinophilic disorders 3